18,315 Shares in CRISPR Therapeutics AG $CRSP Purchased by Nwam LLC

Nwam LLC acquired a new stake in CRISPR Therapeutics AG (NASDAQ:CRSP) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 18,315 shares of the company’s stock, valued at approximately $891,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. ProShare Advisors LLC purchased a new position in shares of CRISPR Therapeutics during the 2nd quarter worth approximately $1,008,000. SFE Investment Counsel grew its holdings in CRISPR Therapeutics by 11.1% during the second quarter. SFE Investment Counsel now owns 7,232 shares of the company’s stock worth $352,000 after acquiring an additional 725 shares during the period. HC Advisors LLC purchased a new position in CRISPR Therapeutics in the second quarter worth $205,000. Mitsubishi UFJ Asset Management Co. Ltd. raised its position in CRISPR Therapeutics by 6.4% in the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 6,091 shares of the company’s stock worth $296,000 after acquiring an additional 366 shares in the last quarter. Finally, Prospera Financial Services Inc acquired a new stake in CRISPR Therapeutics in the second quarter valued at $297,000. Institutional investors and hedge funds own 69.20% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Samarth Kulkarni sold 50,895 shares of the company’s stock in a transaction on Friday, October 17th. The stock was sold at an average price of $67.91, for a total value of $3,456,279.45. Following the sale, the chief executive officer directly owned 254,201 shares in the company, valued at $17,262,789.91. This represents a 16.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, General Counsel James R. Kasinger sold 1,076 shares of the stock in a transaction on Tuesday, October 14th. The shares were sold at an average price of $66.60, for a total value of $71,661.60. Following the sale, the general counsel directly owned 83,402 shares in the company, valued at approximately $5,554,573.20. The trade was a 1.27% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 56,213 shares of company stock worth $3,810,458. 4.10% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on CRSP shares. Bank of America upped their price target on shares of CRISPR Therapeutics from $78.00 to $93.00 and gave the stock a “buy” rating in a research note on Friday, October 17th. Zacks Research raised shares of CRISPR Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 26th. Royal Bank Of Canada upped their target price on shares of CRISPR Therapeutics from $42.00 to $50.00 and gave the stock a “sector perform” rating in a research report on Tuesday. Wells Fargo & Company set a $75.00 target price on shares of CRISPR Therapeutics in a report on Monday, October 13th. Finally, Needham & Company LLC decreased their price target on CRISPR Therapeutics from $81.00 to $80.00 and set a “buy” rating on the stock in a research note on Monday. Eleven research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, CRISPR Therapeutics presently has an average rating of “Hold” and an average target price of $68.11.

CRISPR Therapeutics Trading Up 1.2%

NASDAQ:CRSP opened at $55.21 on Wednesday. The company has a market capitalization of $5.02 billion, a P/E ratio of -9.88 and a beta of 1.89. The firm has a 50-day moving average price of $63.03 and a two-hundred day moving average price of $53.45. CRISPR Therapeutics AG has a twelve month low of $30.04 and a twelve month high of $78.48.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Monday, November 10th. The company reported ($1.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.32) by $0.15. CRISPR Therapeutics had a negative net margin of 1,273.70% and a negative return on equity of 21.49%. The company had revenue of $0.89 million for the quarter, compared to the consensus estimate of $8.74 million. On average, equities research analysts predict that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.